Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Russell 2000 ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.75 (market cap $8.04B), while iShares Russell 2000 ETF trades at $295.96. The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | IWM | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $300.45 |
52-Week Low | $241.71 | $214.95 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
IWM trades at $293.44, down 0.85% on the day amid a bearish technical signal. The ETF shows mixed momentum with moving averages bullish but oscillators neutral, while recent news highlights small-cap outperformance versus large caps year-to-date. Support levels cluster around $289-292 with resistance at $295-298. The Russell 2000 has gained 22.1% YTD according to The Motley Fool (2026-07-02), though some analysts question sustainability amid Fed policy uncertainty.
Outlook remains bifurcated: strong small-cap performance offers growth potential in economic expansion, but higher volatility and interest rate sensitivity pose risks. The ETF's 0.19% expense ratio and diversification across nearly 2,000 stocks provide structural benefits, though valuation concerns persist as passive flows increase exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
